Translational vaccine R&D
TRANSVAC-DS
at a glance
TARGET
Vaccine R&D Infrastructure
TIMELINE
01 June 2020 to 28 Feb 2023
COORDINATOR
European Vaccine Initiative
FUNDER
European Union
FUNDING
1.88 Mio Euro
SUMMARY
Design study for an European vaccine infrastructure
Through the TRANSVAC infrastructure, state-of-the-art scientific-technical services, technical training, and innovative research and development are currently providing very significant support to European vaccine researchers and developers.
TRANSVAC-DS builds on the outstanding success and lessons learned from TRANSVAC and during the two-year project duration will further explore and prepare the establishment of a stable and truly sustainable European vaccine infrastructure. The main objective and output of TRANSVAC-DS is the preparation of a conceptual design report that will describe in detail the maturity of the vaccine infrastructure concept and be the basis for the establishment of a permanent and sustainable vaccine infrastructure of direct relevance to and benefit for Europe and further afield. As part of the design report, a five-year business plan will be delivered together with an implementation plan that will guide the further establishment of a sustainable European vaccine infrastructure.
PARTNERS
BIOASTER - Fondation de Cooperation Scientifique (France), Biomedical Primate Research Centre (BPRC) (The Netherlands), Commissariat a l'energie atomique et aux energies alternatives (CEA/IDMIT) (France), Dutch Ministry of Health and Sport (The Netherlands), European Clinical Research Infrastructure Network (ECRIN) (France), European Infrastructure for Translational Medicine (EATRIS) (The Netherlands), Flanders Vaccines (Belgium), Fraunhofer Institute for Molecular Biology and Applied Ecology IME (Germany), GenIbet Biopharmaceuticals S.A. (Portugal), Helmholtz Centre for Infection Research (HZI) (Germany), Institut de Recerca i Tecnologia Agroalimentàries (IRTA) (Spain), Instituto de Salut Carlos III (Spain), Institut national de la Recherche agronomique (INRA) (France), Instituto de Biologia Experimental e Tecnológica (iBET) (Portugal), Instruct Academic Services Limited (Italy / United Kingdom), Leiden University (LU) (The Netherlands, London School of Hygiene and Tropical Medicine (LSHTM) (United Kingdom), Medicines & Healthcare products Regulatory Agency (United Kingdom), Sciensano (Belgium), Sclavo Vaccine Association (SVA) (Italy), Statens Serum Institut (SSI) (Denmark), University of Siena (UNISI) (Italy), Vaccine Formulation Institute (United Kingdom), Wageningen Bioveterinary Research, Wageningen University & Research (SWR) (The Netherlands).
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 951668.